CytomX Therapeutics Inc

NASDAQ:CTMX   9:47:00 AM EDT
4.13
-0.03 (-0.72%)
Products

CytomX Therapeutics Announces Preliminary Results For Ongoing Phase 2 Expansion Study Of CX-2029

Published: 12/20/2021 21:30 GMT
CytomX Therapeutics Inc (CTMX) - Cytomx Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of Cx-2029, a First-in-class Antibody-drug Conjugate Candidate Targeting Transferrin Receptor, Cd71.
Cytomx Therapeutics Inc - Adverse Event Profile Consistent With Phase 1 Observations.
Cytomx Therapeutics Inc - Look Forward to Completing Expansion Phase of Cx-2029 Development Program and Providing Further Data Updates in 2022.